New Hampshire is currently home to 337 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Lebanon, Manchester, Nashua and Portsmouth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764
Recruiting
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Dartmouth Hitchcock Medical, Lebanon, New Hampshire
Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Immune Profiling for Cancer Immunotherapy Response
NCT06116032
Recruiting
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer
Register for Updates
Wraparound for High-risk Families With Substance Use Disorders: Examining Family, Child, and Parent Outcomes
NCT04637581
Recruiting
The investigators propose a Hybrid Type 1 effectiveness-implementation quasi-experimental trial. Participants are drawn from two different communities contemporaneously. The intervention participants in one community receive a Wraparound intervention. Comparison group participants drawn from a second matched community receive treatment as usual. With this design, the investigators aim to study outcomes associated with the intervention as well as explore important facilitators and barriers associ... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: Dept of Children Youth and Families, Claremont, New Hampshire
Conditions: Substance-Related Disorders, Depression, Stress Disorders, Post-Traumatic, Child Abuse, Child Neglect
Register for Updates
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
NCT04968834
Recruiting
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. U... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
10/31/2023
Locations: Dartmouth-Hitchcock, Lebanon, New Hampshire
Conditions: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome
Register for Updates
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Using a Smartphone App to Target Current Mental Health Symptoms of Anxiety and Depression
NCT06037382
Recruiting
This is a prevention intervention study that will examine the efficacy of a smartphone-based intervention in decreasing cancer risk by targeting mental health risk factors of anxiety and depression.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
10/27/2023
Locations: Dartmouth College, Hanover, New Hampshire
Conditions: Depression, Anxiety, Cancer
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT05933395
Recruiting
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Advanced Breast Cancer
Register for Updates
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
NCT02000115
Recruiting
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/24/2023
Locations: Catholic Medical Center, Manchester, New Hampshire
Conditions: Aortic Valve Stenosis
Register for Updates
HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) -Post-Traumatic Epilepsy (PTE)
NCT05235061
Recruiting
The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-PTE, to improve the quality of life and cognitive function in Service Members, Veterans and civilians with post traumatic epilepsy (PTE). This study will also assess the ability of the HOBSCOTCH-PTE program to improve quality of life in caregivers of PTE patients and to reduce caregiver burden.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Epilepsy, Traumatic, Brain Injuries, Traumatic
Register for Updates
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
NCT03597581
Recruiting
RGX-202-01 (ompenaclid) is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI +/- bevacizumab. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202-01 with or without FOLFIRI +/- bevacizumab (single agent or combination therapy) will be evaluate... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Dartmouth, Lebanon, New Hampshire
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Register for Updates